

Results of 2023 Annual General Meeting

ASX Market Announcements Office
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

The results of Resonance Health Limited's Annual General Meeting held at 10:00 a.m. (WST) on 16 November 2023 are set out in the attached document. All resolutions put to the AGM were decided by a Poll.

For further information please contact:

Mitchell Wells – Non-executive Director & Company Secretary

E: mwells@resonancehealth.com

P: +61 (0)8 9286 5300

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing quantitative assessments essential in managing diseases and drug development. Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, (formerly HepaFat-AI) an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFatSmart® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn, Facebook, and Twitter.

Results of Annual General Meeting held on 16 November 2023

Resolutions voted on at the meeting					Votes cast on the poll					Proxies received			
Resolution		Result	Voting method	If s250U applies	Voted FOR		Voted AGAINST		Abstained*	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%	Number	Number	Number	Number	Number
1	Remuneration Report (Ordinary resolution)	Carried	Poll	N/A	63,545,359	98.60%	902,315	1.40%	1,062,500	53,982,501	902,315	1,062,500	615,162
2	Re-election of Director – Dr Martin Blake (Ordinary resolution)	Carried	Poll	N/A	154,756,926	99.12%	1,377,925	0.88%	510,000	145,149,598	1,377,925	510,000	359,632
3	Re-election of Director – Mr Mitchell Wells (Ordinary resolution)	Carried	Poll	N/A	155,150,804	99.41%	923,047	0.59%	571,000	144,267,946	923,047	1,571,000	635,162
4	Re-election of Director – Mr Aaron Brinkworth (Ordinary resolution)	Carried	Poll	N/A	154,850,804	99.18%	1,273,047	0.82%	521,000	144,967,946	1,273,047	521,000	635,162
5	Approval of 10% Placement Facility (Special resolution)	Carried	Poll	N/A	152,711,960	98.16%	2,856,891	1.84%	1,076,000	143,154,632	2,856,891	1,076,000	309,632
6	Resolution Withdrawn	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
7	Selective Share Buy-back (Special resolution)	Carried	Poll	N/A	80,452,573	98.28%	1,406,202	1.72%	986,076	70,872,245	1,406,202	986,076	332,632

*Votes cast by a person who abstain on an item are not counted in calculating the required majority on a poll.